

# Hikma Algeria Factsheet

**hikma.**

August 2025

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. In Algeria, Hikma is a leading provider of high-quality medicines serving healthcare professionals and patients across the country for over 30 years.



## Local expertise, global strength



**5**  
Manufacturing plants



**860+**  
Employees



**1**  
R&D centre  
in Staoueli

Hikma in Algeria is **ranked #3** among the pharmaceutical companies based on sales<sup>1</sup>

Hikma has a **6% market share** of the total Algerian pharmaceutical market<sup>1</sup>

Hikma was **the 1<sup>st</sup>** to establish an oral **oncology manufacturing plant** in Algeria

## Making healthcare accessible for all

We ensure our world-class medicines are within reach for all, improving access to healthcare in the country

## Manufacturing high-quality medicines

### General formulation plant

Manufactures a variety of medicines in various dosage forms producing approximately 40 million units/year

### Penicillin plant

Manufactures approximately 20 million units/year of penicillin-based antibiotics

### Cephalosporin plant

Produces approximately 10 million units/year of high-quality anti-infectives commonly used to treat bacterial infections

### Oncology plant

First local oral oncology plant with the ability to produce various forms of oral oncology medicines

### Injectables plant

Manufactures a variety of injectable medicines

## A diversified portfolio of medicines

We offer the Algerian patient over 114 medicines covering 8 therapeutic areas to address a wide range of healthcare needs:



Anti-infectives



Oncology



Respiratory



Cardiovascular



Diabetes



Gastrointestinal



Dermatology



Central Nervous System

Hikma was **the 1<sup>st</sup>** multinational pharmaceutical company to register a **locally manufactured product** in Algeria

Hikma is **one of the leading providers** of oral-systemic, oral anti-infectives

Launching an average of **5 new products** in the market annually

Reference:  
1. Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Quarterly value sales data for the countries listed below for the period: MAT Apr. 2025. Market definitions: Includes all therapeutic areas except for those ATC-3 classes that may encompass Nutrients, Infant Formulas, and Diagnostics elements within MIDAS Data, specifically ATCs SIT, T1G, T2X, T3A, V6C, and V6D, in each case reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

### Company information

Vice President - North Africa Territory:  
**Eyad Abuawad**

General Manager Algeria:  
**Abdelkrim Kabeche**

### Hikma Pharmaceuticals - Algeria

15,16 Zone d'activité Staoueli  
Algiers - Algeria

### Contacts

See [www.hikma.com](http://www.hikma.com) for contact forms